Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 18, Issue 24, 2000, Pages 4098-4108

  Gelmon, K A ^a   Latreille, J ^a   Tolcher, A ^a   Genier L ^a   Fisher, B ^a   Forand, D ^a   D'Aloisio, S ^a   Vernillet, L ^a   Daigneault, L ^a   Lebecq, A ^a   Besenval, M ^a   Eisenhauer, E ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RPR 109881A; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

EID: 0034671296     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.24.4098     Document Type: Article

References (26)

1. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
2. Docetaxel (Taxotere): A review of preclinical and clinical experience, Part 1 - Preclincial experience
3. The Taxoids
4. In vivo isolation and characterization of a docetaxel resistant B16 melanoma
5. Continual Reassessment Method: A practical design for phase a clinical trails in cancer
6. Practical modifications of the continual reassessment method for phase 1 cancer clinical trials
7. Phase I clinical trial design in cancer drug development
8. The continual reassessment method (CRM) for dose escalation in phase 1 trials in San Antonio does not result in more rapid study completion
9. Preliminary evaluation of the modified continual reassessment method (MCRM) in four phase 1 studies of RPR109881A
10. Topoisomerase I inhibitors: Review and update
11. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum
12. A phase I and pharmacokinetic study of docetaxel in cancer patients with liver dysfunction due to malignancies
13. A phase I clinical and pharmacokinetic study of RPR 109881A: A new taxoid administered as a 1 hour infusion in patients with solid tumors
14. Phase I trial of RPR 109881A (RPR): A novel taxoid derivative administered as a 24 hour continuous infusion
15. A phase I and pharmacokinetic (PK) study of RPR 109881A given as 6-hour IV infusion in patients (pts) with advanced solid tumors
16. Phase I Study of RPR 109881A in patients with advanced solid tumors
17. Phase II trial of outpatient weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer
18. Weekly docetaxel in patients with advanced refractory malignancies: A Phase I trial
19. Is response in phase I trials a useful predictor for the future clinical activity of a new agent? Proceedings of the Ninth NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1996
20. Preliminary evaluation of the modified continual reassessment method (MCRM) in four phase I studies with RPR 109881A. Tenth NCI EORTC Symposium on New Drugs in Cancer Therapy, 1998
21. Workshop on phase I study design